University Hospital Munich, Department of Internal Medicine IV
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kroiss, Matthias
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
CaboACC, NCT03612232: Cabozantinib in Advanced Adrenocortical Carcinoma

Active, not recruiting
2
37
Europe
Cabozantinib-s-malate
Wuerzburg University Hospital
Adrenocortical Carcinoma
12/24
04/25
NCT03906331: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing
N/A
Europe, Japan, US, RoW
Selpercatinib, LOXO-292, LY3527723
Eli Lilly and Company, Eli Lilly and Company
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
 
 
Schmidmaier, Ralf
CaboACC, NCT03612232: Cabozantinib in Advanced Adrenocortical Carcinoma

Active, not recruiting
2
37
Europe
Cabozantinib-s-malate
Wuerzburg University Hospital
Adrenocortical Carcinoma
12/24
04/25

Download Options